Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px

Document › Details

Ablynx N.V.. (2/23/17). "Press Release: Ablynx Announces 2016 Rull Year Results. Significant Progress in Key Pre-clinical and Clinical Development Programmes". Ghent.

	Organisation	Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)
	Group	Sanofi (Group) [since May 2011]
	Product	caplacizumab (anti-vWF Nanobody)
	Product 2	vobarilizumab (ALX-0061, anti-IL-6R Nanobody)
	Person	Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry)
	Person 2	Vermeersch, Marieke (Galapagos 202112– Head of Corp Communcations before Hyloris + AgroSavfe + Ablynx + Degroof)

Original document
accessed by [iito] on

Record changed: 2023-06-05

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Sanofi (Group) [since May 2011]

[1] Owkin. (3/21/24). "Press Release: Owkin Expands Collaboration with Sanofi Leveraging AI for Drug Positioning in immunology"....
[2] GenSight Biologics S.A.. (12/22/23). "Press Release: GenSight Biologics Appoints Laurence Rodriguez as Chief Executive Officer". Paris....
[3] Sanofi S.A.. (12/11/23). "Press Release: Statement on FTC Challenge to Proposed License Agreement with Maze Therapeutics". Paris....
[4] Aqemia SAS. (12/5/23). "Press Release: Aqemia Announces a Major Multi-year Collaboration of $140 Million with Sanofi". Paris....
[5] Eligo Bioscience S.A.. (12/5/23). "Press Release: Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines". Paris....
[6] MeiraGTx Holdings plc. (10/30/23). "Press Release: MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities". London & New York, NY....
[7] Sanofi S.A.. (10/3/23). "Press Release: Sanofi Announces Agreement for Potential First-in-Class Vaccine against Extraintestinal Pathogenic E. coli". Paris....
[8] Sanofi S.A.. (3/13/23). "Press Release: Sanofi to Acquire Provention Bio, Adding to Portfolio TZIELD, the First Disease-modifying Treatment for the Delay of Stage 3 Type 1 Diabetes (T1D)". Paris & Red Bank, NJ....
[9] Avilar Therapeutics, Inc.. (2/16/23). "Press Release: Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders". Waltham, MA....
[10] Sanofi S.A.. (1/11/23). "Press Release: Sanofi Ventures Announces Multi-year Capital Commitment from Sanofi, Increasing Evergreen Fund to $750M". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]